Furthermore, earlier GHRH antagonists counteracted the mitogenic effects of GHRH in lung cancer cell lines by increasing p53 and inhibiting MAPK activation, as well as the expression of inflammatory iNOS, COX-2 and NF-kB [45]. Here, PTGS2 is linked to lung carcinoma.